Pharmaceuticals

Degron Therapeutics and Takeda Enter into Exclusive License and Collaboration Agreement to Develop Molecular Disintegrators for Multiple Indications

bexib
By bexib 0 Min Read

The joint venture will leverage Degron’s GlueXplorer platform to identify, validate and optimize molecular adhesive breakers.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Synchrony’s AI Training Strategy | Bank Automation News
Next Article Manitoba Crop Alliance sets course for next three years – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Remaking history: Sarah Mather and Aquascope
Manufacturing
Christmas has arrived at Orelle – Luxury Hospitality Magazine
Hospitality & Tourism
A look inside: Allies developing a multicloud hybrid strategy
Banking
2024 Holiday Shipping Deadline for the United States
International Shipping